PA
CAPR icon

Perceptive Advisors’s Capricor Therapeutics CAPR Stock Holding History

Perceptive Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-650,000
Closed -$6.45M – 94
2025
Q2 		$6.45M Buy
+650,000
New +$6.87M 0.24% 61

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors's CAPR Position: Q4 2018 in Review

Perceptive Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2018, closing a stake of 400 shares — an estimated $4K sold.

Perceptive Advisors first reported a position in CAPR in Q1 2015 and held it in 13 quarters. The position peaked at $35K in Q1 2015. 18 funds tracked by Wall St. Rank hold CAPR as of Q4 2018.

  • Perceptive Advisors reported no remaining Capricor Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Perceptive Advisors sold 400 Capricor Therapeutics shares in Q4 2018, an estimated $4K.
  • Perceptive Advisors first reported a position in Capricor Therapeutics in Q1 2015 and held it in 13 quarters.
  • Perceptive Advisors's Capricor Therapeutics position peaked at $35K in Q1 2015.
  • 18 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.